Chola MS records Rs.1997 cr GWP in Q1 FY25-26
(GWP) of Rs 1,997 crore.
On the key financial and operational highlights for Q1 FY25-26, the company said Gross Written Premium (GWP) growth was at 2.7% consequent to the 1/n method of GWP recognition effective October 1, 2024.
The GWP growth was 7.9% on full premium basis. The Company had Rs.102 crs of non-motor long term premium the recognition of which has been deferred to respective annual periods.
Profit Before Tax (PBT) for Q1 was Rs.144.77 Cr as against Rs.178.96 crores in the corresponding quarter.
The Company made a higher provisioning for motor third claims in the context of rising value of awards and absence of any increase in motor third party premium over the last four years.
The results for the quarter were also impacted by a few large claims in the fire line of business. The net worth rose to Rs 3,106 crore as of June 30, 2025 with the solvency ratio at 2.17 times (regulatory requirement of 1.5 times) and recorded a return on equity of 3.45% for the quarter (not annualized).
Commenting on the performance, Mr. V. Suryanarayanan, Managing Director, Chola MS, said, 'We remain steadfast in our pursuit of sustainable and profitable growth. Our continued investments in digital platforms, data-led decision-making, and strategic distribution partnerships have ensured we stay resilient and future-ready. We are committed to enhancing value for our customers, partners,
and stakeholders through innovation, operational excellence, and a strong service ethos.'
UNI GV 1930
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
a few seconds ago
- Economic Times
IndiGo profit falls sharply on geopolitical tension, Air India crash
Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads India's largest airline IndiGo reported a sharp 20% fall in profit as air travel was impacted due to a conflict between India and Pakistan followed by weak travel sentiment after the crash of an Air India aircraft in airline, which has 60% share of India's domestic market, posted a profit of Rs 2,176.3 crore for the April–June period, down 20% from Rs 2,728.8 crore a year ago despite revenue being up by 4.73% at Rs 20,496.30 briefly restricting flights from 32 airports in airports on the north and western border in May amid border skirmishes with Pakistan following a terrorist attack in April.'The June quarter was shaped by significant external challenges that created headwinds for the entire aviation sector. Despite these industry wide disruptions, we reported a net profit margin of around 11% for the quarter ended June 2025,' Pieter Elbers, CEO of indigo a metric for profitability for airlines also dropped by 5% as the airline had to reduce fares to fill aircraft which dropped by a little over 2%.The airline though gave optimistic note and outlined plans for expansion. Elbers said the airline has begun long-haul services to Europe, launching flights to Amsterdam and Manchester in early July. Given strong demand, IndiGo will double its frequency to Amsterdam and add a fourth weekly flight to Manchester. A reciprocal codeshare with KLM will also expand the airline's reach across Europe.'We remain firm on our full year capacity guidance of early double digit capacity addition. While we have taken a number of proactive steps as part of our plan to align capacity with the demand, we are using the downtime to conduct structural inspections on some aircrafts and implementing fleet upgrades, ensuring the fleet is fully prepared for the seasonally strong third quarter,' Chief Financial Officer Gaurav Negi said in a post-results call with debuting on the Delhi–Mumbai route late last year, IndiGo's business class product (called Stretch) has now been extended to flights to Bangkok and will soon launch on routes to Singapore and Dubai. Elbers said the market response has been encouraging, with load factors improving the domestic front, IndiGo recently began operations from Hindon airport in Delhi and is looking to expand its network further.
The Hindu
3 minutes ago
- The Hindu
Hyundai Motor India Q1 net slides 8% to ₹1,369 crore
Hyundai Motor India Ltd. (HMIL) for the first quarter ended June 30, 2025 reported 8% fall in consolidated net profit at 1,369 crore. The company's revenue during the quarter also dropped 5.36% to Rs.16,413 crore from Rs.17,344 crore a year ago. The company witnessed accelerated exports growth and volumes increased 13% on YoY basis, while domestic growth remained subdued, amid macro challenges, the company said in a filing. Unsoo Kim, Managing Director, HMIL said, 'We continued our stated strategy of 'Quality of Growth' in the first quarter of FY26 with balance between domestic & exports, market share and profitability.' 'This strategy helped us to sustain strong EBITDA margin of 13.3% during the quarter, despite tough macro-economic environment,' he said. 'Moving forward, we anticipate gradual recovery in domestic demand sentiments, driven by onset of monsoon & festive season coupled with government policy measures, while on the exports front, we are confident to maintain a positive momentum, in line with our growth commitments,' he added.
&w=3840&q=100)
Business Standard
3 minutes ago
- Business Standard
JB Pharma Q1 profit up 14%, revenue up 9% on domestic segment gains
JB Chemicals and Pharmaceuticals posted a 14.4 per cent increase in its consolidated net profit at Rs 202 crore for the first quarter of the financial year (Q1FY26). Revenue from operations also rose by 8.9 per cent to Rs 1,093 crore. Sequentially, net profit increased by 38 per cent, with revenue also growing by 15 per cent. Nikhil Chopra, chief executive officer and wholetime director, JB Pharma, stated: 'The domestic business recorded approximately 14 per cent value growth. This was driven by acute and chronic segments, including our ophthalmology portfolio. Our major brands and their franchises are also performing well. The CDMO business momentum is likely to sustain in the coming quarters.' Going forward, the company will focus on increasing topline growth along with optimisation of costs and organisational efficiencies. It expects the domestic and CDMO segments to lead growth and profitability. The company claims it is one of the fastest-growing domestic pharmaceutical companies among the top 25 organisations, as per IQVIA MAT June 2025 data. JB Pharma's ophthalmology portfolio delivered robust 19 per cent growth, reaching Rs 57 crore in Q1FY26. The Razel franchise crossed Rs 100 crore in MAT June 2025, up from Rs 69 crore in MAT June 2023, while Azmarda sales rose to Rs 75 crore from Rs 69 crore in MAT June 2024. International business revenue grew 2 per cent year-on-year (Y-o-Y) to Rs 416 crore, compared to Rs 409 crore. However, the international formulations segment declined 2 per cent to Rs 283 crore. While branded generics exports grew during the quarter, markets such as Russia, the US and South Africa remained flat or marginally declined. The CDMO business posted an 8 per cent increase to Rs 115 crore, with strong momentum expected to continue. The active pharmaceutical ingredient (API) segment reported 38 per cent Y-o-Y growth, rising to Rs 18 crore from Rs 13 crore. The results were announced after market hours. JB's share fell by 1.08 per cent, ending the day's trade at Rs 1,782.90 apiece on the BSE.
